Literature DB >> 9210698

In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

J A Vazquez1, M Lynch, D Boikov, J D Sobel.   

Abstract

The in vitro activity of a new pneumocandin, L-743,872, was evaluated with 108 strains of Candida and compared with the activities of various antifungals. L-743,872 demonstrated the best activity against azole-susceptible and -resistant strains of C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. kefyr and less activity against C. krusei, C. lusitaniae, and C. guilliermondii.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9210698      PMCID： PMC163972     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Fungal 1,3-beta-glucan synthase.

Authors:  E Cabib; M S Kang
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

4.  Levels of gamma-glutamyltranspeptidase in cultured skin fibroblasts from cystinotics and normals.

Authors:  B States; S Segal
Journal:  Life Sci       Date:  1980-11-24       Impact factor: 5.037

5.  Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Authors:  F A Bouffard; R A Zambias; J F Dropinski; J M Balkovec; M L Hammond; G K Abruzzo; K F Bartizal; J A Marrinan; M B Kurtz; D C McFadden
Journal:  J Med Chem       Date:  1994-01-21       Impact factor: 7.446

6.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

7.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

8.  Echinocandin inhibition of 1,3-beta-D-glucan synthase from Candida albicans.

Authors:  E T Sawistowska-Schröder; D Kerridge; H Perry
Journal:  FEBS Lett       Date:  1984-07-23       Impact factor: 4.124

9.  Candidiasis in cancer patients.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

10.  Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study.

Authors:  A Cassone; R E Mason; D Kerridge
Journal:  Sabouraudia       Date:  1981-06
View more
  39 in total

1.  Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991.

Authors:  M Lozano-Chiu; P W Nelson; V L Paetznick; J H Rex
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

2.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

3.  Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.

Authors:  Sevtap Arikan; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

4.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

5.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 6.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Elena Alvarez; Fernando Baquero; Ramón Cisterna; Joaquina Gil; Estrella Martín-Mazuelos; Carmen Rubio; Aurora Sánchez-Sousa; Carmen Serrano
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

8.  Caspofungin: the first agent available in the echinocandin class of antifungals.

Authors:  Joseph Rybowicz; Cheryle Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-01

9.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

10.  Sequential therapy with caspofungin and fluconazole for Candida albicans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Isabella Baldassarri; Anna Marigliano; Daniela Arzeni; Daniele Giannini; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.